Of note, a TNFR2 antagonist has a greater effect on suppressing Tregs from the ascites fluid of ovarian cancer patients than Tregs from the peripheral blood of healthy donors110, suggesting the specificity of TNFR2 antagonists for the tumor microenvironment. This evidence concerns the gene TNFRSF1B and ovarian cancer.